Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Receivables - Net (2016 - 2024)

Historic Receivables - Net for Trinity Biotech (TRIB) over the last 11 years, with Q4 2024 value amounting to $2.3 billion.

  • Trinity Biotech's Receivables - Net fell 163.51% to $2.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 billion, marking a year-over-year decrease of 163.51%. This contributed to the annual value of $2.3 billion for FY2024, which is 163.51% down from last year.
  • As of Q4 2024, Trinity Biotech's Receivables - Net stood at $2.3 billion, which was down 163.51% from $2.3 billion recorded in Q4 2023.
  • In the past 5 years, Trinity Biotech's Receivables - Net registered a high of $2.7 billion during Q4 2022, and its lowest value of $3.0 million during Q4 2021.
  • In the last 5 years, Trinity Biotech's Receivables - Net had a median value of $1.1 billion in 2022 and averaged $1.2 billion.
  • Per our database at Business Quant, Trinity Biotech's Receivables - Net plummeted by 2794.41% in 2020 and then soared by 9002056.26% in 2022.
  • Quarter analysis of 5 years shows Trinity Biotech's Receivables - Net stood at $3.9 million in 2020, then fell by 23.87% to $3.0 million in 2021, then skyrocketed by 90020.56% to $2.7 billion in 2022, then decreased by 13.64% to $2.3 billion in 2023, then fell by 1.64% to $2.3 billion in 2024.
  • Its Receivables - Net stands at $2.3 billion for Q4 2024, versus $2.3 billion for Q4 2023 and $2.7 billion for Q4 2022.